Ascendis Pharma
Clinical trials sponsored by Ascendis Pharma, explained in plain language.
Biopharmaceutical company developing therapies for rare endocrine disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Weekly shot shows promise for helping kids with dwarfism grow
Disease control By invitation onlyThis study tests a weekly injection called TransCon CNP in children and teens with achondroplasia, the most common form of dwarfism. The goal is to see if it is safe and helps improve growth over several years. Participants who completed a previous TransCon CNP trial can join thi…
Phase 2/3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug combo aims to boost growth in kids with dwarfism
Disease control OngoingThis study tests whether giving two weekly injections together can improve growth in children aged 2 to 11 with achondroplasia, a common cause of dwarfism. The drugs, navepegritide and lonapegsomatropin, are designed to increase height. The trial will measure growth rate and moni…
Phase 2 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC